Search Results

You are looking at 1 - 10 of 45 items for :

  • "cytoreductive surgery" x
  • Refine by Access: All x
Clear All
Full access

HSR19-110: Predicting Candidates for Cytoreductive Surgery and HIPEC: The Role of Computed Tomography and Diagnostic Laparoscopy

Leigh Selesner, Gabrielle Gauvin, Dorotea Mutabdzic, Eileen O’Halloran, Maxwell Kilcoyne, Kwan-Keat Ang, Jeffrey Farma, Elin Sigurdson, and Sanjay Reddy

Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has led to improved survival in select patients with peritoneal surface malignancies. Predicting the volume of disease and any unresectable disease is

Full access

The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer

Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim

Edited by Kerrin G. Robinson

. J Clin Oncol 2007 ; 25 : 5165 – 5171 . 11. Hoskins WJ Bundy BN Thigpen JT . The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology

Full access

Principles of Surgical Management of Peritoneal Mesothelioma

Jessica A. Steadman and Travis E. Grotz

, 2 Radical resection with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remains the primary curative therapy for malignant peritoneal mesothelioma (MPeM), and the strongest predictor of long-term survival is

Full access

Current Concepts in the Evaluation and Treatment of Patients With Diffuse Malignant Peritoneal Mesothelioma

Keli Turner, Sheelu Varghese, and H. Richard Alexander

this natural history, operative strategies designed to control disease progression within the abdominal cavity have been developed and increasingly used over the past 20 years. Currently, cytoreductive surgery (CRS) together with hyperthermic

Full access

Intraperitoneal Chemotherapy for Ovarian Cancer: Where Are We Now?

Pankaj Singhal and Shashikant Lele

Gynecologic Oncology Group study . J Clin Oncol 2003 ; 21 : 3194 – 3200 . 4. Hoskins WJ McGuire WP Brady MF . The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual

Full access

Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer

Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill

therapy. A small proportion of patients with recurrent ovarian cancer may also be candidates for secondary cytoreductive surgery (SCS) for low-volume, isolated disease, which may be missed without routine surveillance imaging. Recent data suggest that

Full access

Surgery for Ovarian Cancer: Rationale and Guidelines

Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray

experience . J Clin Oncol 1991 ; 9 : 1138 – 1150 . 19 Hacker NF Berek JS Lagasse LD . Primary cytoreductive surgery for epithelial ovarian cancer . Obstet Gynecol 1983 ; 61 : 413 – 420 . 20 Hoskins WJ Bundy BN Thigpen JT . The

Full access

Indications for Minimally Invasive Surgery for Ovarian Cancer

Ernest S. Han and Mark Wakabayashi

Advanced-stage disease (stage III–IV) is diagnosed in 75% to 85% of patients, and standard management generally involves cytoreductive surgery and platinum/taxane-based chemotherapy. 2 Novel strategies and technologies are desperately needed to diagnose

Full access

Metastatic Colon Cancer, Version 3.2013

Featured Updates to the NCCN Guidelines

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

, mortality from colorectal cancer has decreased by almost 35% from 1990 to 2007, 3 likely because of earlier diagnosis through screening and better treatment modalities. Peritoneal Carcinomatosis: Cytoreductive Surgery and Perioperative Hyperthermic

Full access

Ovarian Cancer, Version 3.2012

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer

-front primary debulking (ie, cytoreductive) surgery followed by adjuvant chemotherapy for most patients with resectable advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancers). 17 – 19 Upfront cytoreductive surgery